ERBB2 and breast cancer: Currently, there are two Food and Drug Administration (FDA)-approved HER-2-directed antibody-drug conjugates (ADCs), trastuzumane-emtansine (T-DM1) and trastuzumab-deruxtecan (T-DXd), for HER-2+ metastatic BC (134).